Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC (No 2) [2006] FCA 1787

Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC (No 2) [2006] FCA 1787

The 981 Patent claims encompass both racemic mixtures and individual enantiomers; accordingly, Ranbaxy's intended product would infringe the 981 Patent. The Enantiomer Patent is invalid: the purported claim of surprising and unexpected 10-fold increase in activity for the RR enantiomer over the racemate was not supported by Warner-Lambert's own data, the representations in the specification and to the Patent Office were false and misleading, and the claimed invention did not achieve the promised result and thus lacked the required utility. The Enantiomer Patent is revoked; Ranbaxy is restrained from infringing the 981 Patent.

Jurisdiction
Australia
Judgment Date
20 December 2006
Procedural Posture
Patent Revocation and Infringement Proceedings / Post Trial Judgment
Outcome
Partly in favour of applicant (Ranbaxy) on invalidity of Enantiomer Patent; partly in favour of respondent (Warner-Lambert) on infringement of 981 Patent
Legal Topics
['patent Construction' 'revocation of Patents' 'patent Selection/selection Patents' 'grounds of Invalidity' 'patent Infringement' 'utility' 'false Suggestion or Misrepresentation']
['intellectual Property Law' 'patents'] ['patent Construction' 'revocation of Patents' 'patent Selection/selection Patents' 'grounds of Invalidity' 'patent Infringement' 'utility' 'false Suggestion or Misrepresentation']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Patent Revocation and Infringement Proceedings / Post Trial Judgment

Legal Issues

  1. 1 ['Construction of patent claims (scope of 981 Patent)' 'Whether the Enantiomer Patent should be revoked (manner of manufacture, false suggestion/misrepresentation, utility)' 'Whether proposed importation and sale by Ranbaxy would infringe the 981 Patent']

Ratio Decidendi

The 981 Patent claims encompass both racemic mixtures and individual enantiomers; accordingly, Ranbaxy's intended product would infringe the 981 Patent. The Enantiomer Patent is invalid: the purported claim of surprising and unexpected 10-fold increase in activity for the RR enantiomer over the racemate was not supported by Warner-Lambert's own data, the representations in the specification and to the Patent Office were false and misleading, and the claimed invention did not achieve the promised result and thus lacked the required utility. The Enantiomer Patent is revoked; Ranbaxy is restrained from infringing the 981 Patent.

Court Disposition

Partly in favour of applicant (Ranbaxy) on invalidity of Enantiomer Patent; partly in favour of respondent (Warner-Lambert) on infringement of 981 Patent

Orders

  • ['Australian Letters Patent No 628198 (the Enantiomer Patent) be revoked.' 'Ranbaxy Australia Pty Ltd, its officers, employees, or agents, be restrained during the term of Australian Letters Patent No 601981 (the 981 Patent), and any extension of that term, from infringing claims 1 to 4 (inclusive), 8 and 9 of that...